Corrona Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01402661|
Recruitment Status : Enrolling by invitation
First Posted : July 26, 2011
Last Update Posted : November 10, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
The primary objective for this registry is to systematically collect and document use patterns, effectiveness, and safety of DMARDs (Disease Modifying Anti-Rheumatic Drugs), biologic agents, and any other treatments currently used in the management of RA.
The design is a prospective, non-interventional registry for patients with RA under the care of a rheumatologist. Longitudinal data are collected from both patients and their treating rheumatology providers during routine clinical encounters using a structured and standardized data collection method. The scope of data collection includes but is not limited to patient demographics, disease duration, medical history (including all prior and current treatments for RA), smoking status, alcohol use, disease activity and severity, pain, as well as other clinician- and patient-reported outcomes, comorbidities and adverse events, infections, hospitalizations, and other targeted safety outcomes. After the enrollment visit, RA patients and physicians will complete the follow-up questionnaires during regularly scheduled clinical encounters. The goal is to collect data from patients and providers at six month intervals. Adverse events may be volunteered spontaneously by the subject, or be discovered as a result of general questioning by the Investigator. During all Corrona related visits with the Investigator, subjects will be questioned regarding the occurrence of adverse events.
|Study Type :||Observational|
|Estimated Enrollment :||91758 participants|
|Official Title:||Corrona Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry|
|Study Start Date :||February 2002|
|Estimated Primary Completion Date :||December 2100|
|Estimated Study Completion Date :||December 2100|
Pts presenting to enrolling sites across the US are invited to enroll if eligible.
- Patterns, effectiveness, and safety of DMARDs, biologic agents and any other treatments currently used in the management of RA [ Time Frame: Data are collected on subjects for as long as they consent to remain in the study ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Be at least 18 years of age or older.
- Be able and willing to provide written consent for participation in the registry as well as Personally Identifiable Information (PII) that includes Full Name and Date of Birth at a minimum.
- Have been diagnosed with rheumatoid arthritis by a rheumatologist.
- Meet at least one of the following criteria:
(A) Currently receiving an Eligible Medication** that was started within 365 days of the Enrollment Visit.
i. A temporary interruption of an Eligible Medication is allowed if the interruption in treatment lasted <180 days.
(B) Prescribed or receiving the first dose of an Eligible Medication** on the day of the Enrollment Visit.
(C) Diagnosed with RA within 365 days of the Enrollment Visit regardless of treatment regimen ("Early RA").
The patient must not:
- Have a diagnosis of Juvenile idiopathic arthritis (JIA), Psoriatic arthritis (PsA), Spondyloarthritis (SpA), Ankylosing spondylitis (AS), Systemic lupus erythematosus (SLE), or any other form of autoimmune inflammatory arthritis.
- Be starting only a non-eligible medication, unless the patient was diagnosed with RA within 365 days of the Enrollment Visit. Non-eligible medications include conventional DMARDs - for example methotrexate, sulfasalazine, leflunomide, etc. - and including prednisone.
Be participating in or planning to participate in a double-blind randomized clinical trial of an RA drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded.
Early Follow-Up Visit Criteria
To be eligible for an early Corrona Follow-Up Visit that is conducted <150 days since the last registry visit, the following conditions must be met:
A follow-up set of questionnaires should always be completed whenever a registry subject is being prescribed or receiving the first dose of a new (different) Eligible Medication** at a routine office visit. If this occurs less than 150 days from the previous visit at which Corrona questionnaires had been completed, it is considered an "Early Follow-Up Visit." The next anticipated visit that follow-up questionnaires would be completed would be calculated off the Early Follow-up Visit date (=>150 days). Prior use of an Eligible Medication** does not exclude a patient from an Early Follow-Up visit.
- Eligible Medications are biologics, biosimilars, and JAK-inhibitors FDA-approved for the treatment of RA. Prior use of an Eligible Medication does not exclude a patient from enrollment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01402661
|United States, New York|
|Center for Rheumatology|
|Albany, New York, United States, 12206|
|Study Director:||Joel Kremer, MD||Center for Rheumatology|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Other Study ID Numbers:||
|First Posted:||July 26, 2011 Key Record Dates|
|Last Update Posted:||November 10, 2022|
|Last Verified:||November 2022|
Connective Tissue Diseases
Immune System Diseases